Fig. 12.

PcS-MA nanomedicines-potentiated mPTT synergizing with PDT for tumor ablation. (A) Fabrication of a theranostic nanoparticle via the supramolecular interaction between PcS and MA, nucleic acid-triggered fluorescent imaging, and combinational therapy of PTT, PDT and CH6T; (B) Immunofluorescence images of mice bearing MCF7 tumors after treatment. Tumor hypoxic regions (anti-HIF1-α, green), blood vessels and angiogenesis (anti-CD31, red) and nuclei (DAPI) were detected, respectively. Scale bars indicate 100 µm; (C) Quantitative analysis of hypoxia-positive cells in the immunofluorescence images. Data are expressed as mean ± SEM; (D) The relative tumor volume of the investigated groups, with the data normalized to the volumes at Day 0. The tumors were treated with laser (690 nm, 1 W/cm² for 5 min) at 4 h post injection. Data are expressed as mean ± SEM (n = 5, *P < 0.05, **P < 0.01). Reproduced with permission from [114]. Copyright 2018 American Chemical Society.